Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | GRM6 | O15303 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | LHCGR | P22888 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30300589 | 0.81 | KDM4E (0.46) | ALDH1A1KDM4EKMT2ACA12CA1 | |
| SCHEMBL27833792 | 0.81 | GRM6 (0.39) | ALDH1A1KDM4EGRM6KMT2AHPGDS | |
| SCHEMBL27580623 | 0.79 | GRM6 (0.43) | ALDH1A1GRM6KMT2AHPGDSLMNA | |
| SCHEMBL21543944 | 0.77 | GRM6 (0.43) | ALDH1A1KDM4EGRM6KMT2AHPGDS | |
| SCHEMBL3239531 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4EKMT2AL3MBTL1POLB | |
| SCHEMBL20303179 | 0.74 | ALDH1A1 (0.49) | ALDH1A1KDM4EKMT2AL3MBTL1LMNA | |
| Methane SCHEMBL27538360 | 0.74 | KDM4E (0.35) | KDM4EGRM6KMT2ACA12CA1 | |
| SCHEMBL1767847 | 0.72 | KDM4E (0.40) | ALDH1A1KDM4EGRM6KMT2ACA12 | |
| SCHEMBL23460236 | 0.72 | ESR1 (0.38) | ALDH1A1KDM4ELMNA | |
| SCHEMBL23460234 | 0.72 | ESR1 (0.38) | ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4252856-A2 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | Oligomerix, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3558950-B1 | NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE | OLIGOMERIX INC (US) | 2023-05-10 | — | — | EP | disclosed |
| EP-1572072-A4 | METHODS OF TREATING INFECTION BY DRUG RESISTANT BACTERIA | GENESOFT INC (US) | 2009-04-01 | — | — | EP | disclosed |
| US-7498405-B2 | Halogen-substituted thienyl compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-20060287247-A1 | Binds nucleic acids; microbiocides for Grampositive infections and drug resistance bacteria | GENESOFT PHARMACEUTICALS, INC. (US) | 2006-12-21 | — | — | US | disclosed |
| US-7122626-B2 | Halogen-substitued thienyl compounds | GENESOFT PHARMCEUTICALS, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1572072-A2 | METHODS OF TREATING INFECTION BY DRUG RESISTANT BACTERIA | Genesoft, Inc. (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004043335-A2 | METHODS OF TREATING INFECTION BY DRUG RESISTANT BACTERIA | GENESOFT, INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20030199516-A1 | Methods of treating infection by drug resistant bacteria | GENESOFT, INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030130198-A1 | Halogen-substitued thienyl compounds | GENESOFT, INC. (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2002088119-A1 | HALOGEN-SUBSTITUTED THIENYL COMPOUNDS | GENESOFT PHARMACEUTICALS, INC (US) | 2002-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287247-A1 | Binds nucleic acids; microbiocides for Grampositive infections and drug resistance bacteria | CNBP, TLR9, DDB1 | ALDH1A1 3152/4885KDM4E 2315/4885GRM6 1584/4885 |
| US-20030199516-A1 | Methods of treating infection by drug resistant bacteria | POLI, POLN, PCNA | ALDH1A1 3899/4885KDM4E 3892/4885GRM6 2665/4885 |
| US-20030130198-A1 | Halogen-substitued thienyl compounds | TOP1, TPR, PCNA | ALDH1A1 2611/4885KDM4E 1519/4885GRM6 4286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.